BE624199A - - Google Patents
Info
- Publication number
- BE624199A BE624199A BE624199DA BE624199A BE 624199 A BE624199 A BE 624199A BE 624199D A BE624199D A BE 624199DA BE 624199 A BE624199 A BE 624199A
- Authority
- BE
- Belgium
- Prior art keywords
- product
- soluble
- desc
- page number
- clms page
- Prior art date
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 210000002307 Prostate Anatomy 0.000 description 4
- 230000001195 anabolic Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000001548 androgenic Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- AQSJGOWTSHOLKH-UHFFFAOYSA-N Phosphite Chemical compound [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 210000004291 Uterus Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- GRXPVLPQNMUNNX-STEDVDCISA-N estrane Chemical compound C1CC2CCCCC2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 GRXPVLPQNMUNNX-STEDVDCISA-N 0.000 description 2
- 230000001076 estrogenic Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- GRXPVLPQNMUNNX-UHFFFAOYSA-N 13-methyl-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthrene Chemical compound C1CC2CCCCC2C2C1C1CCCC1(C)CC2 GRXPVLPQNMUNNX-UHFFFAOYSA-N 0.000 description 1
- XHRCFGDFESIFRG-UHFFFAOYSA-N 2-chloro-N-ethyl-N-[(2-methylphenyl)methyl]ethanamine Chemical compound ClCCN(CC)CC1=CC=CC=C1C XHRCFGDFESIFRG-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010003549 Asthenia Diseases 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101710045274 GPANK1 Proteins 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 101700004563 LON1 Proteins 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- DUQGREMIROGTTD-UHFFFAOYSA-N Monuron-TCA Chemical compound OC(=O)C(Cl)(Cl)Cl.CN(C)C(=O)NC1=CC=C(Cl)C=C1 DUQGREMIROGTTD-UHFFFAOYSA-N 0.000 description 1
- 244000278455 Morus laevigata Species 0.000 description 1
- 235000013382 Morus laevigata Nutrition 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N Nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 241000786363 Rhampholeon spectrum Species 0.000 description 1
- 210000001625 Seminal Vesicles Anatomy 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L Sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 210000003371 Toes Anatomy 0.000 description 1
- 241000710779 Trina Species 0.000 description 1
- 230000035507 absorption Effects 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000001016 myotrophic Effects 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE624199A true BE624199A (ru) |
Family
ID=195994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE624199D BE624199A (ru) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE624199A (ru) |
-
0
- BE BE624199D patent/BE624199A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0001029B1 (fr) | Procédé de préparation d'oximes en 3 de stéroides | |
| CA1216283A (fr) | Amino-14 steroides, leur application en therapeutique et procede pour leur preparation | |
| BE624199A (ru) | ||
| Wren et al. | XLVI.—Studies in the phenylsuccinic acid series. Part III. The optically active phenylsuccinic acids and their derivatives | |
| EP0044575B1 (fr) | Produits intermédiaires dans la synthèse de 19-nor stéroides substitués en position 2 | |
| DE1443123C (de) | Verfahren zur Herstellung von 13 Alkyl gona 1,3,5(10) tnenen | |
| DE752371C (de) | Verfahren zur Herstellung von Enolaethern von 3-Ketosteroiden | |
| CH388975A (fr) | Procédé de préparation d'un dérivé de la réserpine | |
| Hope et al. | LXXXII.—The condensation of ethyl crotonate and ethyl methylacrylate with ethyl cyanoacetate and ethyl bromoacetate. Synthesis of γ-methylbutane-αβ δ-tricarboxylic acid and pentane-αβ δ-tricarboxylic acid | |
| US1062203A (en) | Manufacture and production of alkyl derivatives and substituted alkyl derivatives of hydrocupreine. | |
| BE525044A (ru) | ||
| CH629826A5 (en) | Steroids, process for preparing them and their use in the synthesis of tritium-labelled steroids | |
| BE594849A (ru) | ||
| BE564226A (ru) | ||
| CH352669A (de) | Verfahren zur Herstellung von 16-Keto-steroiden | |
| CH347523A (fr) | Procédé de préparation de diesters des 9x-halogéno-16x-hydroxy-hydrocortisones | |
| DD273838A1 (de) | Verfahren zur herstellung von 17(20)-ungesaettigten steroid-21-saeuren bzw. ihren derivaten | |
| DE1443123B (de) | Verfahren zur Herstellung von 13 Alkyl gona 1,3,5(10) tnenen | |
| IL26373A (en) | 3-acetylthioethoxy and 3-acetylthiopropoxy steroids of the estrane,androstane and pregnane series,their preparation and their use | |
| CH442286A (fr) | Procédé de préparation de nouveaux pyrazolostéroïdes | |
| CH299700A (fr) | Procédé de préparation de 17B-acétyl- 4,7,9-androstatriène-3-one. | |
| CH345887A (fr) | Procédé de préparation de dérivés de la 1-déhydro-adrénostérone | |
| BE686511A (ru) | ||
| CH432512A (fr) | Procédé de préparation de stéroïdes 21-bromés | |
| BE678891A (ru) |